toloxatone has been researched along with Parkinson Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Petzer, A; Petzer, JP; Terre'Blanche, G; Van der Walt, MM | 1 |
| Legoabe, LJ; Petzer, A; Petzer, JP; Qhobosheane, MA | 1 |
| Legoabe, LJ; Meiring, L; Petzer, A; Petzer, JP | 1 |
| Hitge, R; Petzer, A; Petzer, JP | 1 |
| Dostert, P; Strolin Benedetti, M | 1 |
1 review(s) available for toloxatone and Parkinson Disease
| Article | Year |
|---|---|
Overview of the present state of MAO inhibitors.
Topics: Animals; Benzamides; Humans; Hydrazines; Isoquinolines; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Parkinson Disease; Phenethylamines; Piperidines; Selegiline; Structure-Activity Relationship | 1987 |
4 other study(ies) available for toloxatone and Parkinson Disease
| Article | Year |
|---|---|
Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B.
Topics: Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship; Styrenes | 2017 |
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
Topics: Chemistry Techniques, Synthetic; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quinazolinones; Structure-Activity Relationship | 2018 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propylamines; Selegiline; Tetrahydronaphthalenes; Tyramine | 2022 |
The inhibition of monoamine oxidase by 2H-1,4-benzothiazin-3(4H)-ones.
Topics: Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2022 |